Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
XNCR
XNCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XNCR News
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Dec 17 2025
SeekingAlpha
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
Dec 09 2025
Newsfilter
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Nov 06 2025
Benzinga
RBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19
Nov 06 2025
Benzinga
Could Xencor's (XNCR) Preliminary Cancer Findings Indicate a New Advantage in Its Innovation Approach?
Oct 28 2025
Yahoo Finance
Xencor Unveils Preliminary Findings for XmAb819, a Novel ENPP3 x CD3 Bispecific T-Cell Engager Targeting Clear Cell Renal Cell Carcinoma
Oct 24 2025
Newsfilter
Xencor to Hold Webcast and Conference Call to Review Preliminary Findings from the Ongoing Phase 1 Dose-Escalation Trial of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Oct 21 2025
Newsfilter
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market
Oct 17 2025
Newsfilter
Strategies for Profiting from Tax-Loss Selling Before Year-End
Oct 02 2025
MarketWatch
Our Calculations Show RWJ Could Reach $54
Sep 25 2025
NASDAQ.COM
Erasca, Candle, Xencor Decline Following BofA Downgrade Due to Absence of Immediate Catalysts
Sep 03 2025
SeekingAlpha
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/3/2025
Sep 03 2025
TipRanks
In-Depth Insights: Four Analysts Weigh In on Xencor Stock
Sep 02 2025
Benzinga
Wells Fargo Maintains Overweight on Xencor, Lowers Price Target to $27
Aug 07 2025
Benzinga
Wedbush Maintains Outperform on Xencor, Lowers Price Target to $26
Aug 07 2025
Benzinga
Xencor (XNCR) Q2 Revenue Jumps 82%
Aug 06 2025
NASDAQ.COM
Show More News
